The Evolution of the Treatment of Acid-Related Diseases

S.M. Tkach, A.E. Dorofeiev

Abstract


The article describes the main stages of the development and improvement of antisecretory therapy, from antacids to modern proton pump inhibitors (PPIs). It is concluded that at present the main drugs for the treatment of acid-related diseases are PPIs, which are conditionally divided into drugs of I and II generation. II generation drugs are more effective and safe, as they are less dependent on CYP2C19 polymorphism and have the least potential for side effects and drug-drug interactions. The safest PPI for the long-term treatment of acid-related diseases, especially if it is necessary to administer other drugs, is pantoprazole.


References


Abraham N.S., Hlatky M.A., Antman E.M. et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American college of cardiology foundation task force on expert consensus documents // J. Am. Coll. Cardiol. — 2010. — 56 (24). — 2051-2066.

Andersson K., Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases // Pharmacol. Ther. — 2005. — 108. — 294-307.

Banerjee S., Weideman R.A., Weideman M.W. et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention // Am. J. Cardiol. — 2011. — 107. — 871-878.

Beil W., Staar U., Sewing K. Pantoprazole: a novel H+/K+-ATPase inhibitor with an improved pH stability // Eur. J. Pharmacol. — 1992. — 218. — 265-271.

Bhatt D.L., Cryer B.L., Contant C.F. et al. Clopidogrel with or without omeprazole in coronary artery disease // N. Engl. J. Med. — 2010. — 363 (20). — 1909-1917.

Chaudhry A.S., Kochhar R., Kohli K.K. Genetic polymorphism of CYP2C19 and therapeutic response to proton pump inhibitors // Indian J. Med. Res. — 2008. — 127 (6). — 521-530.

Dent J., Kahrilas P.J., Hatlebakk J., Vakil N., Denison H., Franze´n S., Lundborg P. A randomized, comparative trial of a potassium competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease // Am. J. Gastroenterol. — 2008. — 103. — 20-26.

Edwards S.J., Lind T., Lundell L. Systematic review: proton pump inhibitors PPIs for the healing of reflux oesophagitis: a comparison of esomeprazole with other PPIs // Aliment. Pharmacol. Ther. — 2006. — 24. — 743-50.

Fandriks L., Lonroth H., Pettersson A., Vakil N. Can famotidine and omeprazole be combined on a once-daily basis? // Scand. J. Gastroenterol. — 2007. — 42. — 689-694.

Hagymási K., Müllner K., Herszényi L., Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors // Pharmacogenomics. — 2011. — 12 (6). — 873-888.

Hatlebakk J.G. Review article: gastric acidity: comparison of esomeprazole with other proton pump inhibitors // Aliment. Pharmacol. Ther. — 2003. — 17 (Suppl. 1). — 10-15.

Huang J.Q., Hunt R.H. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physician // Best Pract. Res. Clin. Gastroenterol. — 2001. — 15. — 355-370.

Hunt R.H. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005 // Aliment. Pharmacol. Ther. — 2005. — 22 (Suppl. 3). — 10-19.

Howden C.W. Review article: immediate-release proton-pump inhibitor therapy: potential advantages // Aliment. Pharmacol. Ther. — 2005. — 22 (Suppl. 3). — 25-30.

Hunt R.H., Armstrong D., James C., Chowdhury S.K., Yuan Y., Fiorentini P., Taccoen A., Cohen P. Effect on intragastric pH of a PPI with a prolonged plasma half-life — comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers // Am. J. Gastroenterol. — 2005. — 100. — 1949-1956.

Katz P.O., Scheiman J.M., Barkun A.N. Review article: acid-related disease: what are the unmet clinical needs? // Aliment. Pharmacol. Ther. — 2006. — 23 (Suppl. 2). — 9-22.

Katz P.O., Koch F.K., Ballard E.D., Bagin R.G., Gautille T.C., Checani G.C., Hogan D.L., Pratha V.S. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms // Aliment. Pharmacol. Ther. — 2007. — 25. — 197-205.

Kendall M.J. Review article: Esomeprazole: the first proton pump inhibitor to be developed as an isomer // Aliment. Pharmacol. Ther. — 2003. — 17 (Suppl. 1). — 1-4.

Kromer W., Horbach S., Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis // Pharmacology. — 1999. — 59. — 57-77

Miner P.B. Jr, Katz P.O., Chen Y., Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study // Am. J. Gastroenterol. — 2003. — 98. — 2616-2620.

Modlin I.M., Sachs G., Wright N., Kidd M. Edkins and a century of acid suppression // Digestion. — 2005. — 72. — 129-145.

Sachs G. Synthesis or Rupture: duration of acid inhibition by PPIs. Research Highlights Driving Therapeutic Advance // ALTANA Pharma Symposium. October, 20, 2002, Geneva. — 9-10.

Scarpignato C., Galmiche J.P. The role of H2-receptor antagonists in the era of proton pump inhibitors // Guidelines for Management of Symptomatic Gastro-oesophageal Reflux Disease / Edited by Lundell L. Science Press. — 1998. — 55-66.

Scarpignato C., Pelosini I., Di Mario F. Acid suppression the-rapy: where do we go from here? // Dig. Dis. — 2005. — 24. — 7-42.

Scarpignato C., Hunt R. Proton pump inhibitors: the beginning of the end or the end of the beginning? // Current Opinion in Pharmacology. — 2008. — 8. — 677-684

Scarpignato C., Pelosini I. Review article: the opportunities and benefits of extended acid suppression // Aliment. Pharmacol. Ther. — 2006. — 23 (Suppl. 2). — 23-34.

Sharma P., Shaheen N.J., Perez M.C., Pilmer B., Lee M., Peura DA. TAK-390MR, a proton pump inhibitor (PPI) with a no-vel dual delayed release (DDR) formulation, is highly effective in the healing of erosive esophagitis (EE). — data from two randomized controlled trials // Gastroenterology. — 2008. — 134 (Suppl. 1). — A-171 [Abstract#S1073].

Shin J.M., Homerin M., Domagala F., Ficheux H., Sachs G. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+-ATPase in vitro and in vivo // Biochem Pharmacol. — 2006. — 71. — 837-849.

Simon W.A., Herrmann M., Klein T., Shin J.M., Huber R., Senn-Bilfinger J., Postius S. Soraprazan: setting new standards in inhibition of gastric acid secretion // J. Pharmacol. Exp. Ther. — 2007. — 321. — 866-874.

Tytgat G.N. Shortcomings of the first-generation proton pump inhibitors // Eur. J. Gastroenterol. Hepatol. — 2001. — 13 (Suppl. 1). — S29-S33.




DOI: https://doi.org/10.22141/2308-2097.4.58.2015.81586

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru